Study title: A phase II, two-centre, open-label study in patients aged 3 months to 13 years with endoscopically-proven reflux oesophagitis.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Digestive System Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: LANSOPRAZOLE | |||||
| ATC code: A02BC03 | |||||
| Document link: Lansoprazole_AG-II-95-028-Synopsis.pdf | |||||
| Document date: 2011-10-14 | |||||
| Study number: AG/II/95/028-EC384 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | Y | Y | - | |